pipobroman has been researched along with Leukemia, Myeloid in 13 studies
Pipobroman: An antineoplastic agent that acts by alkylation.
pipobroman : An N-acylpiperazine that is piperazine in which each of the nitrogens has been acylated by a 3-bromopropionoyl group. An anti-cancer drug.
Leukemia, Myeloid: Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pipobroman (PB) is a neutral amide of piperazine with a chemical structure close to that of alkylating agents, although the exact mechanism of action of PB has not been demonstrated." | 6.42 | Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman. ( Lazzarino, M; Passamonti, F, 2003) |
| "An analysis of the risk of progression towards leukemia, carcinoma and myelofibrosis was performed in 93 patients treated by 32P alone (PVSG protocols) since 1970-1979, 395 patients over the age of 65 years treated by 32P with or without maintenance therapy using hydroxyurea (French protocol) since 1980-1994, and 202 patients under the age of 65 treated by either hydroxyurea or pipobroman since 1980." | 6.18 | Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias". ( Dresch, C; Echard, M; Goguel, A; Grange, MJ; Lejeune, F; Najean, Y; Rain, JD, 1996) |
| "Acute myeloid leukaemia, myelofibrosis and solid tumours occurred in three, two and seven patients with a 10-year cumulative risk of 3%, 2% and 7% respectively." | 5.31 | Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. ( Astori, C; Baratè, C; Bernasconi, P; Brusamolino, E; Canevari, A; Cazzola, M; Corso, A; Lazzarino, M; Malabarba, L; Orlandi, E; Pascutto, C; Passamonti, F, 2002) |
| " Randomized studies have shown that the risk of thrombosis was significantly reduced in ET with the use of hydroxyurea (HU) and in PV with the use of chlorambucil or 32P." | 4.80 | Treatment of polycythaemia vera and essential thrombocythaemia. ( Silverstein, MN; Tefferi, A, 1998) |
| "Pipobroman (PB) is a neutral amide of piperazine with a chemical structure close to that of alkylating agents, although the exact mechanism of action of PB has not been demonstrated." | 2.42 | Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman. ( Lazzarino, M; Passamonti, F, 2003) |
| "Acute myeloid leukaemia, myelofibrosis and solid tumours occurred in three, two and seven patients with a 10-year cumulative risk of 3%, 2% and 7% respectively." | 1.31 | Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. ( Astori, C; Baratè, C; Bernasconi, P; Brusamolino, E; Canevari, A; Cazzola, M; Corso, A; Lazzarino, M; Malabarba, L; Orlandi, E; Pascutto, C; Passamonti, F, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (46.15) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernasconi, P | 2 |
| Boni, M | 1 |
| Cavigliano, PM | 1 |
| Calatroni, S | 1 |
| Brusamolino, E | 2 |
| Passamonti, F | 3 |
| Volpe, G | 1 |
| Pistorio, A | 1 |
| Giardini, I | 1 |
| Rocca, B | 1 |
| Caresana, M | 1 |
| Lazzarino, M | 3 |
| Bernasconi, C | 1 |
| Juncá Piera, J | 1 |
| Durán Suárez, JR | 1 |
| Triginer Boixeda, J | 1 |
| Najean, Y | 1 |
| Rain, JD | 1 |
| Dresch, C | 1 |
| Goguel, A | 1 |
| Lejeune, F | 1 |
| Echard, M | 1 |
| Grange, MJ | 1 |
| Sánchez Fayos, J | 1 |
| Román Barbero, A | 1 |
| Nevado Reviriego, I | 1 |
| Tefferi, A | 2 |
| Silverstein, MN | 1 |
| Malabarba, L | 1 |
| Orlandi, E | 1 |
| Pascutto, C | 1 |
| Astori, C | 1 |
| Baratè, C | 1 |
| Canevari, A | 1 |
| Corso, A | 1 |
| Cazzola, M | 1 |
| Bilski-Pasquier, G | 1 |
| Blanc, CM | 1 |
| Bousser, J | 1 |
| Böhnel, J | 1 |
| Stacher, A | 1 |
| Brichta, G | 1 |
| Reimer, EE | 1 |
| Stoiber, T | 1 |
4 reviews available for pipobroman and Leukemia, Myeloid
| Article | Year |
|---|---|
Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman.
Topics: Abortion, Spontaneous; Acute Disease; Alkylating Agents; Female; Humans; Leukemia, Myeloid; Middle A | 2003 |
Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".
Topics: Actuarial Analysis; Acute Disease; Carcinoma; Cause of Death; Disease Progression; Follow-Up Studies | 1996 |
[Efficacious treatment of a fatal blood disease: polycythemia vera].
Topics: Acute Disease; Alkylating Agents; Busulfan; Chlorambucil; Humans; Hydroxyurea; Leukemia, Myeloid; Le | 1997 |
Treatment of polycythaemia vera and essential thrombocythaemia.
Topics: Adult; Aged; Aspirin; Chlorambucil; Disease Progression; Female; Hemorrhage; Humans; Hydroxyurea; In | 1998 |
1 trial available for pipobroman and Leukemia, Myeloid
| Article | Year |
|---|---|
Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".
Topics: Actuarial Analysis; Acute Disease; Carcinoma; Cause of Death; Disease Progression; Follow-Up Studies | 1996 |
9 other studies available for pipobroman and Leukemia, Myeloid
| Article | Year |
|---|---|
Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Chromosome Aberrations; Female; Humans; H | 2002 |
[Osteolytic lesions in chronic myeloid leukemia. Report of three cases (author's transl)].
Topics: Adult; Aged; Bone Neoplasms; Bone Resorption; Busulfan; Female; Humans; Leukemia, Myeloid; Male; Mer | 1981 |
Is hydroxyurea leukemogenic in essential thrombocythemia?
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Bone Marrow; Busulfan; Chromosome Aberrations; Chr | 1998 |
Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle A | 2002 |
Evaluation of two antineoplastic agents, PIPOBROMAN (vercyte) and thioguanine.
Topics: Antineoplastic Agents; Humans; Leukemia, Myeloid; Pipobroman; Polycythemia Vera; Thioguanine | 1967 |
Drugs in the treatment of leukemia.
Topics: Asparaginase; Busulfan; Chlorambucil; Cyclophosphamide; Cytarabine; Humans; Hydroxyurea; Leukemia; L | 1968 |
[Treatment of Vaquez's polycythemia with 1-4, bis-3-bromopropionyl-piperazine. Study of 36 cases].
Topics: Aged; Antineoplastic Agents; Bromine; Erythrocyte Count; Female; Humans; Leukemia, Myeloid; Leukopen | 1968 |
[On the effect of a new cytostatic drug in chronic myeloses and polycythemias].
Topics: Animals; Antineoplastic Agents; Bromine; Chronic Disease; Erythrocyte Count; Erythropoiesis; Female; | 1968 |
[Chronic myelosis. Clinical picture and therapy].
Topics: Antineoplastic Agents; Busulfan; Chronic Disease; Gold Isotopes; Leukemia, Myeloid; Pipobroman; Sple | 1969 |